Investor Presentation
Perth, Mar 6, 2015 AEST (ABN Newswire) - PhytoTech Medical Limited (
ASX:PYL) is focused on the research and development of products for administering MGC, and new treatments utilising MGC therapeutic components for various medical conditions.
The Company is backed by a strong intellectual property portfolio, working in conjunction with leading Israeli research centers, utilising decades of medical cannabis research leadership and science/evidence-based patient trials.
The Company has an exclusive research and licensing agreement with Yissum, the prestigious Research and Development and technology transfer Company of Hebrew University in Jerusalem.
In parallel, PhytoTech Medical is developing strategic alliances with other medical cannabis companies around the world to acquire sophisticated genetic plant strains and already established growing operations.
To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-PYL-711975.pdf
About MMJ Group Holdings Ltd
![Phytotech Medical ASX:PYL](https://abnnewswire.net/images/logos/37064en.jpg)
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/
Related Companies
Social Media
Share this Article